viewInnoCan Pharma

InnoCan Pharma collaborating with Recipharm in Israel to synthesize and analyze cannabinoid-loaded exosomes

Recipharm unites more than 30 facilities across 10 different countries offering pharmaceutical development and manufacturing services

Exosomes, extracellular vesicles, are being explored as a means of drug deliver and to repair damaged cells

InnoCan Pharma Corporation (CNSX:INNO) announced Thursday it is collaborating with Recipharm in Israel to synthesize and analyze cannabinoid-loaded exosomes.

In layman’s terms, exosomes are extracellular vesicles, crucial in cell–to-cell communication which are being explored as a means of drug delivery. Also, the small vesicles that are created when stem cells are multiplied can target and help repair damaged cells. 

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. 

READ: InnoCan Pharma inks deal securing CBD for its coronavirus treatment collaboration with Tel Aviv University and other R&D projects

Recipharm unites more than 30 facilities across 10 different countries offering a range of services, mainly in two different operating areas -- pharmaceutical development services and manufacturing service.

InnoCan said Recipharm offers a wide range of GMP-compliant services ranging from manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices.

"Working closely with the exceptional Recipharm team will allow InnoCan Pharma to devote efforts with the exosome technology production/loading technology while the work on the cannabinoids themselves will be done at Recipharm," InnoCan CEO Iris Bincovich said in a statement.

Potential for different formulations

Dr Sylvia Kachalsky, site manager for Recipharm in Israel, said the project has the potential to be applied to a large spectrum of different indications. 

“The idea of loading Exosomes with Cannabinoids may open a wide window to different formulations, using the Exosome as a 'targeted missile' leading the chosen Cannabinoid to its target," she added.

Professor Daniel Offen, who is leading InnoCan’s research, said the project will look to produce exosomes with CBD, adding that “the development of the CLX- CBD loaded Exosome is very challenging but holding huge potential.”

Israel-based InnoCan has previously stated that the exosomes could be used as treatments for coronavirus (COVID-19) and central nervous system disorders.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: InnoCan Pharma

Price: 0.41 CAD

Market: CSE
Market Cap: $72.04 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...


Innocan Pharma closes financing while launching new commercial website...

Innocan Pharma (CSE: INNO- OTCPINK: INNPF) CEO Iris Bincovich joined Steve Darling from Proactive with news the company has launched a new consumer website for the sale of their products. The site is shop.innocanpharma.com Bincovich also told Proactive about their recent closing of their...

1 week, 6 days ago

2 min read